PE-22-28

PE-22-28 is a synthetic peptide derived from spadin, a fragment that comes from a precursor protein involved in sortilin/neurotensin receptor biology. It was developed in the laboratory as a tool to block a specific potassium channel called TREK-1, which sits in the membrane of certain brain cells and influences how excitable those cells are. The interest in this target grew from research suggesting TREK-1 plays a role in mood regulation.

The core idea is that blocking TREK-1 can increase neuronal signaling in mood-related circuits and may promote effects associated with antidepressant action, such as enhanced serotonergic transmission and signs of increased neuroplasticity in animal models. In rodent studies, spadin and related peptides have been reported to produce antidepressant-like behavioral effects relatively quickly, which is why this target attracted attention.

The honest summary is that PE-22-28 is an obscure, early-stage research compound. The available evidence is almost entirely preclinical -- cell and rodent studies -- and well-designed human clinical data are essentially lacking. It is not an approved drug, its safety in people is unknown, and any claims of antidepressant or neuroprotective benefit in humans go well beyond what has actually been demonstrated.